BTIG Rates Cartesian Therapeutics (RNAC) buy, $44 Price Target

BTIG maintains its buy rating for Cartesian Therapeutics with a $44 price target, a 362.67% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:09 AM EDT · Updated Jun 15, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Cartesian Therapeutics, Inc. ($RNAC) "buy" with a $44 price target on June 9, 2026.

Since the rating, $RNAC is up 32.1% after 1 week, up 41.2% after 1 month and down 8.5% to date (from the $6.85 close on Jun 9, 2026).

RNAC Cartesian Therapeutics, Inc.

$6.27 -7.25% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating on Cartesian Therapeutics, Inc. (RNAC) with a $44 price target on June 9, 2026.
BTIG's $44 price target implies 362.67% upside from Cartesian Therapeutics, Inc.'s ($RNAC) current $9.51 share price.
Shares of RNAC traded near $8.40, with a market cap of $279.4 million and a 52-week range of $5.60 to $15.57.
Insider activity includes significant purchases and sales, while analysts maintain a strong buy consensus with a mean target of $34.57.

Get $RNAC trade alerts by text

We text you when insiders, Congress or big funds trade $RNAC. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cartesian Therapeutics, Inc. alert may contain errors. Disclosures

BTIG has reiterated its buy rating on Cartesian Therapeutics, Inc. (NasdaqGM: RNAC), setting a price target of $44. This action occurred on June 9, 2026, as part of BTIG's ongoing analysis of the company.

Analysts Set New Price Targets

On June 9, 2026, BTIG reiterated its buy rating on Cartesian Therapeutics with a target price of $44. Other analysts have also maintained positive outlooks. Needham maintained its buy rating with a $40 target on May 26, 2026, and HC Wainwright & Co. kept its buy rating with a $25 target on May 12, 2026. The consensus among analysts is a strong buy, with a mean target price of $34.57 based on seven opinions.

Other Institutional Activity in Cartesian Therapeutics

Several institutional investors have adjusted their positions in Cartesian Therapeutics. Squarepoint Ops LLC made a substantial increase, adding 2,220,273 shares, bringing its total to 2,238,486 shares valued at about $13.8 million. FMR LLC reduced its holdings by 567,246 shares, now holding 799,743 shares worth $4.9 million. BlackRock, Inc. trimmed its position slightly, selling 10,588 shares to hold 599,108 shares valued at $3.7 million. Vanguard Capital Management LLC entered with 407,597 shares valued at $2.5 million, and 683 Capital Management, LLC boosted its stake by 50,000 shares to 330,000 shares worth approximately $2 million.

Cartesian Therapeutics, Inc. Stock Up 18.4%

Shares of Cartesian Therapeutics, Inc. (NasdaqGM: RNAC) traded near $8.40. The company has a market capitalization of $279.4 million. Its stock has seen a 52-week low of $5.60 and a high of $15.57. The 50-day moving average is $6.95, while the 200-day moving average is $7.72. Cartesian has a current ratio of 7.65 and a quick ratio of 7.46, indicating strong liquidity.

12-month forecast

$RNAC price target

Cartesian Therapeutics, Inc. daily closes and this analyst's $44 target. Not advice.

Insider Buying and Selling at Cartesian Therapeutics, Inc.

Recent insider activity at Cartesian Therapeutics included both buying and selling. On April 2, 2026, Elizabeth Hoge purchased 758,001 shares and sold 22,740 shares. Similarly, Murat Kalayoglu bought 758,001 shares and sold 22,740 shares on the same date. Additionally, Michael Singer sold 6,555 shares on March 13, 2026, and Christopher Jewell, the Chief Scientific Officer, sold 9,000 shares at an average price of $7.66 on January 13, 2026.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., headquartered in Frederick, Maryland, is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. Its lead product, Descartes-08, is an mRNA CAR-T cell therapy in Phase 2b trials for treating autoimmune diseases like generalized myasthenia gravis and systemic lupus erythematosus. The company is also advancing Descartes-15, an early-stage therapy for multiple myeloma. Cartesian is led by CEO Dr. Carsten Brunn and employs approximately 75 people.

Bottom Line

BTIG's reiterated buy rating with a $44 target reflects continued confidence in Cartesian Therapeutics' potential. Investors track these updates to gauge market sentiment and company prospects. Remember, analyst ratings are one of many tools investors use, and this reiteration is part of a larger picture of Cartesian's market position.